Diverse approaches to diagnosing and treating cancer patients has also enabled comparative effectiveness research evaluating deployment of advanced cancer therapies and associated outcomes [60, 61], and utilization of KRAS and Lynch Syndrome testing to inform metastatic colorectal cancer treatment [62, 63, 64, 65]. The gene discussed is KRAS; the disease is cancer.